RESEARCH PROGRAM

Solid Tumor

"We seek to elucidate the mechanisms that promote carcinogenesis and metastasis of solid tumors with the aim of identifying and validating new molecular markers and therapeutic targets."

DR. RUBÉN PÍO OSÉS
DIRECTOR. SOLID TUMOR RESEARCH PROGRAM

Cancer remains one of the most important health problems in the world. In Europe, around 3.5 million new cases are diagnosed each year and almost 2 million people die of cancer. It is estimated that the number of cases diagnosed annually will increase to more than 4 million in the next 10 years. More than 95% of cancer cases are solid tumors and, of these, one in four are tumors derived from the respiratory tract, mainly lung cancer.

In the Solid Tumors Program we try to identify the molecular mechanisms underlying the transformation of a normal cell into a malignant tumor capable of invading other organs. From this knowledge, we develop strategies for early diagnosis and treatment accompanied by predictive markers of response or resistance that allow a more personalized clinical management of the oncological patient.

To carry out our research we have access to in vitro and in vivo models, collections of clinical samples and methods and devices for genetic, cellular and imaging analysis.

In line with the strategic plan of the Cancer Center of the Universidad de Navarra (CCUN), our priority is to translate the research of the Solid Tumors Program to clinical practice through the application of personalized medicine. Therefore, our research team has a strong multidisciplinary character, with an outstanding participation of clinical researchers. In addition, we maintain close collaboration with the departments of the Clínica Universidad de Navarra involved in the diagnosis and treatment of cancer patients.

We also actively participate in collaborative networks and regional, national and international consortia, such as the Navarra Health Research Institute (IdisNA), the Spanish Lung Cancer Group (GECP), the Center for Biomedical Research Network in Cancer (CIBERONC), International Association for the Study of Lung Cancer (IASLC - Staging and Prognostic Factors Commission), International Early Lung Cancer Action Program (I-ELCAP) or European Network for the Study of Cholangiocarcinoma (ENS-CCA), among others.

Need more information?

If you are interested in learning more about our research, please contact us.

Objectives of the Solid Tumor Program

Understanding the mechanisms involved in the origin of solid tumors

We investigate the molecular processes that promote carcinogenesis and metastasis of solid tumors.

Develop diagnostic and predictive markers of response

We identify and validate markers that help in the early detection of tumors or that allow the selection of the most appropriate treatment for each patient.

Identifying new therapeutic targets

We are looking for new molecular targets to develop more specific and effective therapeutic strategies.

NEW TREATMENTS

To understand the origin and development of solid tumors

We seek new treatments for tumor types for which there are no suitable therapeutic options, as well as for tumors that have developed resistance to treatment.

Solid Tumor Program Research Groups

We seek to improve therapeutic alternatives against cancer

Adhesion and metastasis

Knowledge of the genetic and epigenetic molecular mechanisms with metastatic and/or recurrent potential of tumors.

Biomarkers and new therapeutic targets in lung cancer

Search for diagnostic, prognostic and predictive markers in cancer and new therapeutic targets in lung cancer.

Predictive markers of response

Discovery of aspects of direct clinical applicability in the field of lung cancer.

Preclinical models and analysis tools

Development of new image acquisition techniques and their use for the diagnosis and characterization of cancerous processes.

Oncogenes and effector targets

Identification of new molecular targets in KRAS-dependent tumors and discovery of innovative therapeutic strategies for these tumors.

Advanced therapies for pediatric solid tumors

Development of new therapeutic strategies for childhood brain tumors and sarcomas.

FROM THE LABORATORY TO THE PATIENT

Cutting-edge translational research

In order for our research to reach the cancer patient, we work in very close collaboration with the departments of the Clínica Universidad de Navarra involved in the diagnosis and treatment of cancer. We are part of the Multidisciplinary Areas of the Cancer Center of the Universidad de Navarra (CCUN) and we interact continuously with the Departments of Pediatrics, Pneumology, Oncology, Thoracic Surgery, Neurology, Neurosurgery, Radiology, Anatomic Pathology, Clinical Biochemistry and Nuclear Medicine.


Early detection of lung cancer

We are part of the lung cancer early detection program of the Clínica Universidad de Navarra.


Immunotherapy combinations

We innovate in the design of new therapeutic strategies that enhance the antitumor response of our immune system.


Potentiation of radiotherapy

We evaluate the mechanisms of response to radiotherapy in order to enhance its efficacy and minimize its side effects.

<p>Fachada del Centro de Investigaci&oacute;n M&eacute;dica Aplicada (CIMA)</p>

Would you like to help us?

Thanks to the generosity of many people, the Cima Universidad de Navarra is a reality that strives to offer therapeutic solutions to achieve personalized medicine for patients.

Meet the research team

Scientific Activity of the
Solid Tumors Research Program

1 de january de 2018
Advanced Therapies for Pediatric Solid Tumors
Completed

Immunovirotherapy for childhood osteosarcoma

Cima Principal Investigator: Ana Patiño García
Funded by: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria. Subprograma de Proyectos de Investigación en Salud
1 de january de 2017
Advanced Therapies for Pediatric Solid Tumors
Completed

Therapies for Childhood Solid Tumors

Cima Principal Investigator: Ana Patiño García
Funded by: Fundación ACS